Skip to main content

Find Clinical Trials

Home
Conditions
Iparomlimab and Tuvonralimab Injection

Clinical trial condition

Iparomlimab and Tuvonralimab Injection

Explore clinical trials studying Iparomlimab and Tuvonralimab Injection. Study availability and eligibility vary by location and protocol.

3 public trials 2 recruiting studies

Refine in advanced search Browse all conditions

Iparomlimab and Tuvonralimab Injection trial results

Recruiting

Efficacy and Safety Study of DC-CIK Cell Therapy Combined With Epaloliposide, Vortexil, and Regorafenib as Third-line Treatment for Advanced Colorectal Cancer.

NCT07343791

Conditions: Colonic Diseases, Colorectal Cancer, Colorectal Neoplasms, +13 more
Locations: Jinling Hospital Nanjing, Jiangsu, China

View Trial Details

Recruiting

QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT

NCT07327788

Conditions: Bevacizumab, Hepatecellular Carcinoma, Iparomlimab and Tuvonralimab Injection, +3 more
Locations: Nanfang Hospital of Southern Medical University Guangzhou, Guangdong, China

View Trial Details

Not Yet Recruiting

A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk

NCT07515469

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +11 more
Locations: Not specified

View Trial Details